RedChip Companies will present interviews with First Phosphate Corp. and BioVie Inc. on its television program, Small Stocks, Big Money™. The segments are scheduled to air on Bloomberg TV on Saturday, August 15, at 7:00 p.m. Eastern Time (ET), and on CNBC the following day, Sunday, August 16, at 11:00 a.m. ET.
During his appearance, John Passalacqua, Founder and CEO of First Phosphate, will outline the company's advancements in its Bégin-Lamarche phosphate project. He will delve into the significance of developing a domestically integrated supply chain for lithium iron phosphate (LFP) batteries within North America. Passalacqua will also highlight the recent acquisition of approximately $21.5 million in non-repayable funding from the Canadian government, which is intended for improving infrastructure and facilitating the project's progression towards feasibility and regulatory approval.
Cuong Do, President and CEO of BioVie, will discuss the results of a Phase 2 clinical trial of bezisterim for treating Parkinson's disease. He will emphasize noteworthy improvements in patient conditions compared to placebo groups, along with findings that indicate the drug's potential effects on neuroinflammation. Additionally, Do will detail company plans regarding future trials and regulatory engagements, particularly in connection to their ongoing long COVID study, which is fully enrolled.
Both companies feature prominently in sectors experiencing growth trends. First Phosphate’s efforts align with expanding demand for LFP materials across diverse applications like energy storage and robotics. Meanwhile, BioVie is at the forefront of treating neurological disorders and explores market opportunities tied to long COVID treatment. However, both firms face inherent challenges, such as executing their strategic plans and adhering to regulatory requirements.
The companies featured on the show include First Phosphate Corp. (NASDAQ:PHOS)(CSE:PHOS)(OTCQX:FRSPF)(FSE:KD0) and BioVie Inc. (Nasdaq:BIVI). Both companies are clients of RedChip Companies.
John Passalacqua, CEO of First Phosphate, will discuss the company's Bégin-Lamarche phosphate project and its strategy to build a vertically integrated supply chain for lithium iron phosphate (LFP) batteries in North America. He will also address recent government funding and the expected growth of demand for LFP materials.
Cuong Do, CEO of BioVie, will discuss the results from a Phase 2 clinical trial of bezisterim for Parkinson's disease, highlighting improvements versus placebo and ongoing studies for long COVID and liver disease treatments. These discussions will touch upon regulatory plans and clinical advancements.
The interviews will air on Bloomberg TV on Saturday, August 15, at 7:00 p.m. ET, and on CNBC on Sunday, August 16, at 11:00 a.m. ET.
First Phosphate aims to develop a mine-to-market supply chain for LFP battery production, integrating high-purity phosphate resources into purified phosphoric acid and LFP cathode materials. This is intended to support local production needs, though risks include regulatory obstacles and market demand volatility.
BioVie is focusing on completing the analysis of its Phase 2 trial for bezisterim, preparing for potential future trials, and exploring partnership discussions. However, the company faces challenges common in clinical research, including regulatory approvals and market competition.
The release contains forward-looking statements that involve various risks and uncertainties, such as the ability to execute business strategies, secure funding, and obtain necessary regulatory approvals. Actual results may differ significantly from these expectations due to these material risks.
RedChip Companies is an investor relations and media firm that assists microcap and small-cap companies. They produce the RedChip Small Stocks, Big Money™ show, providing a platform for companies like First Phosphate and BioVie to discuss their operations and strategies.